Avidity Biosciences Past Earnings Performance
Past criteria checks 0/6
Avidity Biosciences's earnings have been declining at an average annual rate of -38.5%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been growing at an average rate of 11.4% per year.
Key information
-38.5%
Earnings growth rate
15.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 11.4% |
| Return on equity | -27.8% |
| Net Margin | -4,136.0% |
| Last Earnings Update | 31 Mar 2025 |
Recent past performance updates
Recent updates
Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Apr 23
Avidity Biosciences: Looks Tempting, But Wait For Interim Phase 3 Data
Feb 24Companies Like Avidity Biosciences (NASDAQ:RNA) Are In A Position To Invest In Growth
Jan 01Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term
Oct 02Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders
Aug 16Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67
Aug 14Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)
Aug 11Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade
Jun 14Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline
May 19Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Mar 01Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch
Feb 29Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?
Nov 04Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Apr 08Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation
Nov 17Avidity slips 20% as FDA places lead asset on partial clinical hold
Sep 27We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth
Jul 29Avidity stock rises amid Chardan starting coverage with Buy
Jul 20Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides
Jul 12Revenue & Expenses Breakdown
How Avidity Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 25 | 9 | -369 | 106 | 33 |
| 31 Dec 24 | 11 | -322 | 86 | 0 |
| 30 Sep 24 | 10 | -280 | 74 | 0 |
| 30 Jun 24 | 11 | -252 | 64 | 0 |
| 31 Mar 24 | 11 | -229 | 56 | 0 |
| 31 Dec 23 | 10 | -212 | 54 | 0 |
| 30 Sep 23 | 10 | -202 | 48 | 0 |
| 30 Jun 23 | 10 | -193 | 45 | 0 |
| 31 Mar 23 | 10 | -192 | 41 | 0 |
| 31 Dec 22 | 9 | -174 | 38 | 0 |
| 30 Sep 22 | 8 | -162 | 35 | 0 |
| 30 Jun 22 | 8 | -148 | 31 | 0 |
| 31 Mar 22 | 8 | -128 | 29 | 0 |
| 31 Dec 21 | 9 | -118 | 26 | 0 |
| 30 Sep 21 | 10 | -96 | 24 | 0 |
| 30 Jun 21 | 9 | -78 | 21 | 0 |
| 31 Mar 21 | 8 | -62 | 17 | 0 |
| 31 Dec 20 | 7 | -44 | 13 | 0 |
| 30 Sep 20 | 6 | -38 | 10 | 0 |
| 30 Jun 20 | 5 | -34 | 7 | 0 |
| 31 Mar 20 | 4 | -28 | 6 | 0 |
| 31 Dec 19 | 2 | -25 | 5 | 0 |
| 31 Dec 18 | 0 | -11 | 2 | 0 |
Quality Earnings: RNA is currently unprofitable.
Growing Profit Margin: RNA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RNA is unprofitable, and losses have increased over the past 5 years at a rate of 38.5% per year.
Accelerating Growth: Unable to compare RNA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: RNA has a negative Return on Equity (-27.79%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/09 20:07 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Avidity Biosciences, Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Tazeen Ahmad | BofA Global Research |